Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2010 Aug;58(3):533-43.
doi: 10.1016/j.yhbeh.2010.04.003. Epub 2010 Apr 24.

The Effects of Progesterone Pretreatment on the Response to Oral D-Amphetamine in Women

Affiliations
Free PMC article
Controlled Clinical Trial

The Effects of Progesterone Pretreatment on the Response to Oral D-Amphetamine in Women

Stephanie C Reed et al. Horm Behav. .
Free PMC article

Abstract

Stimulant abuse continues to be a problem, particularly for women. There is increasing preclinical and clinical evidence showing that the hormone progesterone attenuates the behavioral effects of cocaine, and this effect is primarily observed in females. The purpose of the present study was to determine if progesterone would also alter the behavioral effects of another stimulant, oral d-amphetamine (AMPH) in women. Eighteen normal non-drug abusing women completed eight outpatient sessions over two menstrual cycles. During the follicular phase of each cycle, women were administered AMPH (0, 10, 20 mg); in one cycle they were pretreated with oral micronized progesterone (200 mg) and in another cycle they were pretreated with placebo progesterone. Each session, participants completed a range of tasks including subjective measures of abuse liability, cognitive performance tasks, and behavioral measures of impulsivity and risk-taking. AMPH produced dose-related increases in positive subjective effects and these effects were enhanced by progesterone pretreatment. AMPH alone, or in combination with progesterone, had little effect on performance or behavioral measures of impulsivity. These results are in contrast with previous studies showing that progesterone attenuates the subjective response to cocaine and nicotine. Additional studies are needed to explore the modulatory role of progesterone on the effects of AMPH to determine whether progesterone has any clinical utility for AMPH abuse.

Figures

Fig. 1
Fig. 1
Peak ratings of Good Drug Effect and Drug Liking on the DEQ and peak crossover point for choosing drug over money on the Multiple Choice Procedure as a function of pretreatment and AMPH dose. * denotes a significant difference compared to 0 mg AMPH after placebo pretreatment (p ≤ 0.05). # denotes a significant difference compared to 0 mg AMPH after progesterone pretreatment (p ≤ 0.05). ⊓ denotes a significant difference between pretreatments at that AMPH dose (p ≤ 0.05). Error bars represent + 1 SEM.
Fig. 2
Fig. 2
Peak BDI, state anxiety, POMS Positive Mood and BAES Sedation scores as a function of pretreatment and AMPH dose. * denotes a significant difference compared to 0 mg AMPH after placebo pretreatment (p ≤ 0.05). # denotes a significant difference compared to 0 mg AMPH after progesterone pretreatment (p ≤ 0.05). Error bars represent + 1 SEM.
Fig. 3
Fig. 3
Peak DSST correct arrays as a function of pretreatment and AMPH dose. # denotes a significant difference compared to 0 mg AMPH after progesterone pretreatment (p ≤ 0.05). ⊓ denotes a significant difference between pretreatments at that AMPH dose (p ≤ 0.05). Error bars represent + 1 SEM.
Fig. 4
Fig. 4
Peak IMT ratio, DMT ratio and GoStop ratio as a function of pretreatment and AMPH dose. # denotes a significant difference compared to 0 mg AMPH after progesterone pretreatment (p ≤ 0.05). ⊓ denotes a significant difference between pretreatments at that AMPH dose (p ≤ 0.05). Error bars represent + 1 SEM.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback